Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OFIX
OFIX logo

OFIX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Orthofix Medical Inc (OFIX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.910
1 Day change
-3.33%
52 Week Range
16.990
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Orthofix Medical Inc (OFIX) is not a strong buy at the moment for a long-term beginner investor with $50,000-$100,000 available for investment. The stock lacks immediate positive catalysts, has mixed technical indicators, and its financial performance shows declining profitability. While analysts maintain a generally positive outlook with Buy ratings, the price targets have been lowered, and the company's growth trajectory appears uncertain in the near term.

Technical Analysis

The MACD histogram is slightly positive at 0.0269, indicating mild bullish momentum, but it is contracting. RSI is neutral at 42.032, suggesting no clear overbought or oversold conditions. Moving averages are converging, which does not indicate a strong trend. The stock is trading near its support level of 12.121, with resistance at 12.866. Overall, the technical indicators are mixed and do not strongly favor a buy.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
5

Positive Catalysts

  • Analysts maintain Buy ratings on the stock, with a positive outlook on the company's efforts to reshape its investment story. Gross margin has improved YoY, indicating operational efficiency.

Neutral/Negative Catalysts

  • The company's net income and EPS have significantly declined YoY, reflecting poor profitability. Analysts have lowered their price targets, and the company's longer-term EBITDA margin target has been delayed. No significant hedge fund or insider trading activity has been observed, and there are no recent news catalysts. Congress trading data is also absent.

Financial Performance

In Q4 2025, revenue increased by 1.97% YoY to $219.91M, but net income dropped by 92.38% YoY to -$2.22M. EPS also declined by 92% YoY to -$0.06. Gross margin improved by 4.03% YoY to 69.7%, but overall profitability remains a concern.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a generally positive outlook with Buy ratings from Stifel, Canaccord, and Barrington, but price targets have been lowered to a range of $17-$20. TD Cowen initiated coverage with a Hold rating and a $14 price target, citing the need for evidence of accelerating sales before the stock can perform well.

Wall Street analysts forecast OFIX stock price to rise
3 Analyst Rating
Wall Street analysts forecast OFIX stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.910
sliders
Low
18
Averages
21.33
High
24
Current: 11.910
sliders
Low
18
Averages
21.33
High
24
Stifel
Buy -> Buy
downgrade
$22 -> $18
AI Analysis
2026-03-09
Reason
Stifel
Price Target
$22 -> $18
AI Analysis
2026-03-09
downgrade
Buy -> Buy
Reason
Stifel lowered the firm's price target on Orthofix to $18 from $22 and keeps a Buy rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
Canaccord
Buy
downgrade
$24 -> $20
2026-02-26
Reason
Canaccord
Price Target
$24 -> $20
2026-02-26
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Orthofix to $20 from $24 and keeps a Buy rating on the shares. The firm updated its model to reflect Q4 results and 2026 guidance.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OFIX
Unlock Now

People Also Watch